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Background: Environmental enteric dysfunction (EED) is an acquired syndrome of impaired gastrointestinal
mucosal barrier function that is thought to play a key role in the pathogenesis of stunting in early life. It has been
conceptualized as an adaptive response to excess environmental pathogen exposure. However, it is clinically similar
to other inflammatory enteropathies, which result from both host and environmental triggers, and for which
immunomodulation is a cornerstone of therapy.
Methods: In this pilot double-blind randomized placebo-controlled trial, 44 children with severe acute malnutrition
and evidence of EED were assigned to treatment with mesalazine or placebo for 28 days during nutritional rehabilitation.
Primary outcomes were safety and acceptability of the intervention.
Results: Treatment with mesalazine was safe: there was no excess of adverse events, evidence of deterioration in
intestinal barrier integrity or impact on nutritional recovery. There were modest reductions in several inflammatory
markers with mesalazine compared to placebo. Depression of the growth hormone – insulin-like growth factor-1 axis
was evident at enrollment and associated with inflammatory activation. Increases in the former and decreases in
the latter correlated with linear growth.
Conclusions: Intestinal inflammation in EED is non-essential for mucosal homeostasis and is at least partly maladaptive.
Further trials of gut-specific immunomodulatory therapies targeting host inflammatory activation in order to optimize
the growth benefits of nutritional rehabilitation and to address stunting are warranted. Funded by The Wellcome Trust.
Trial registration: Registered at Clinicaltrials.gov NCT01841099.
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Environmental enteric dysfunction (EED, previously called
environmental or tropical enteropathy) is an acquired syn-
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idemiologic concept that lacks formal criteria for case def-
inition but is considered to play a central role in the
pathogenesis of stunting in early life. It may be a critical
obstacle underlying the strikingly poor impact of even
intensive nutritional and hygiene interventions on
growth faltering [4]. Undernutrition (including acute
malnutrition and stunting) remains the most import-
ant risk-factor for childhood mortality, responsible for
an estimated 45% of all deaths among children under
five years old worldwide, alongside huge burdens oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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growth and developmental potential [5–10].
EED has features of an inflammatory enteropathy:
histopathological changes of small intestinal villous atro-
phy and crypt hyperplasia are accompanied by lympho-
cytic infiltration of the lamina propria [11,12]. Linear
growth failure is associated with detectable products of
Th1 signaling and neutrophil extravasation in stool [13,14].
Systemic inflammatory activation results from breakdown
in mucosal barrier function with consequent translocation
of exogenous antigens alongside luminal bacteria and their
products [5,15]. It has been suggested that gastrointestinal
luminal contents drive this inflammation via specific
enteric pathogens, a global increase in pathogen bur-
den (due to high feco-oral transmission) or altered
microbiota [4,16–18]. However, in all other inflammatory
intestinal diseases of childhood, aberrant or inappropriate
host response plays a critical role in the pathogenesis,
even where an intraluminal trigger is evident [19]. In ce-
liac disease, for example, although antigen-specific T cell
activation is the hallmark, bystander induction of innate
and other immune components contributes to tissue dam-
age and sustained pathology [20].
A key unanswered question is whether intestinal in-
flammation in EED is an appropriate, adaptive response
to excessive pathogen exposure that mitigates the impact
of acute and chronic enteric infections or if it is mal-
adaptive, with host-driven immunopathology contribut-
ing to mucosal barrier breakdown and growth failure. A
maladaptive response would be a rational target for
treatment with immunomodulatory or immunosuppres-
sive agents such as the aminosalicylate mesalazine, which
is commonly used to induce remission of mild to moder-
ate pediatric ulcerative colitis and for maintenance of re-
mission of ulcerative colitis and Crohn’s disease [21–23].
We conducted a pilot clinical trial with a primary ob-
jective of investigating the safety and acceptability of
mesalazine as an adjunctive treatment for children
with severe acute malnutrition (SAM). Acutely mal-
nourished children are at very high risk of ongoing
growth failure despite nutritional rehabilitation and their
degree of intestinal barrier dysfunction has been corre-
lated with outcome [24]. The trial was designed with in-
tensive follow-up in order to detect any indication that the
strategy was interfering with a beneficial, adaptive re-
sponse. Secondary objectives were to collect hypothesis-
generating data relating to inflammatory activation and
growth.
Methods
This was a single-center double-blind randomized placebo-
controlled trial on the use of mesalazine alongside standard
medical and nutritional care in severely acutely malnour-
ished children. Randomization was balanced 1:1.Participants and setting
The study took place between June and November 2013
at the nutrition clinic of Baraka Health Centre, Mathare,
Nairobi. The Baraka Health Centre (BHC) is run by ‘German
Doctors’, a registered non-governmental organization, and
provides free healthcare to children under five years old.
Mathare is the second largest urban slum in Kenya, home to
at least 200,000 people who mostly live in overcrowded
iron-sheet housing with limited access to safe water
and sanitation facilities [25].
Participants were recruited from among those self-
presenting to BHC or via a program of active case-finding
in the community conducted by local community health
workers (CHWs). Eligible participants were children
12- to 60-months old with SAM, defined for the pur-
poses of this study as mid-upper arm circumference
(MUAC) <11.5 cm or bilateral pedal edema. They had
uncomplicated SAM (that is, good appetite and no se-
vere clinical illness) and were, therefore, eligible for
outpatient management according to World Health
Organization (WHO) guidelines [26]. EED was inferred
on the basis of stunting (height-for-age z-score < −2 using
the WHO 2006 growth standards) and chronic inflamma-
tion (erythrocyte sedimentation rate (ESR) >20 mm/hour).
Children were excluded if they had any of the following:
HIV-infection, tuberculosis, bloody diarrhea, biochemical
evidence of renal or hepatic impairment, thrombocytopenia
or severe anemia. Children were also excluded if they were
already receiving treatment for SAM from another center,
if they had medical difficulties precluding normal feeding
(for example, severe cerebral palsy), if they had known pre-
existing renal disease, asthma, hypersensitivity to salicylates
or if they were on medication known to interfere with the
action of the study drug. The exclusion criteria were de-
cided on the basis of contraindications listed in the Sum-
mary of Product Characteristics, pre-existing conditions
that the investigator group felt increased the risk to partici-
pants (for example, HIV infection, bloody diarrhea, other
overt infection requiring hospital admission), or likely futil-
ity in the presence of other major medical problems (for
example, tuberculosis, cerebral palsy) [27]. We did not con-
sider concurrent or recent viral infection or administration
of a live viral vaccine to be a contraindication to adminis-
tration. Although Reye’s syndrome has historically been as-
sociated with salicylate (mainly aspirin) use in these
circumstances, we were unable to find even a single report
of Reye’s associated with mesalazine, and such cautions are
not advised when it is used in the context of inflammatory
bowel disease (IBD).
Screening, enrollment and randomization
Children, 12- to 60-months old, with SAM and stunting
were regarded as potentially eligible and were referred to
the study team for screening. If clinical eligibility was
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provided by the child’s parent or guardian, venous blood
was taken for HIV testing, full blood count, ESR, cre-
atinine, liver function tests, and film for malaria para-
sites, if required. Final screening with blood results took
place the following day, after which eligible children
were enrolled by assigning the next consecutive study
number.
A randomization schedule was developed in STATA
(version 12.0) with variable block sizes (two, four and
six) using the following code: ‘ralloc blknum blksiz Rx,
nsubj(44) osize(3) ntreat(2) saving(mys) table’ [28]. Allo-
cations were assigned to study numbers by the trial stat-
istician (GF). Sachets of mesalazine (Pentasa) granules
and matched placebo were purchased from Ferring
Pharmaceuticals (Saint-Prex, Switzerland) in 2 g foil sa-
chets that were identical apart from labelling. Prior to
initiation of the trial, sachets were disguised by applica-
tion of opaque ‘black-out’ labels (Avery) and re-labelled
(with the study number) by pharmacy staff independent of
the trial team, according to the randomization schedule.
Dosing of drug and placebo was performed on the
basis of weight, which required the contents of the 2 g
sachets to be separated into smaller individual doses.
Pharmacy technicians at BHC were trained to dispense
the study drug using an electronic fine-scale balance (TX-
323 L, Shimadzu). Doses were packed in foil pouches (pur-
chased locally), heat-sealed to render them impermeable to
light and air and labelled with the participant’s initials,
study number and date. The study drug was dispensed
weekly in order to minimize deterioration of the active
product due to repackaging and account for changes in
participants’ weight. Active and placebo granules were
indistinguishable.
Treatment
Participants were prescribed 30 mg/kg/day of mesalazine
or placebo in three divided doses for the first seven days.
Then, if tolerated (see below), the dosage was increased
to 45 mg/kg/day for a further 21 days. They were
followed up for a further 28 days after stopping the
study drug (56 days total). Blood and stool were col-
lected at days 7, 28 and 56. To account for excipients
the dose of granules prescribed was 11 mg/kg three
times daily for the first week, followed by 16.5 mg/kg
three times daily. Because dispensing exactly to the
milligram was not possible with a granular product,
technicians dispensed in the range of the prescribed
dose to prescribed dose + 5 mg.
If recognized side-effects of mesalazine occurred in
the first week or the day 7 blood tests indicated deterior-
ation in renal or hepatic function or blood dyscrasia
(Grade 1 or 2 toxicity), the dosage was maintained at
30 mg/kg/day without unblinding. Such children werere-assessed after a week and their dose was escalated if
or when it appeared to be safe to do so. The study drug
was to be discontinued in the event of Grade 3 or 4 tox-
icity. Toxicity grades for biochemical indices were de-
fined according to the US Division of Microbiology and
Infectious Diseases’ Pediatric Toxicity Tables, 2007 [29].
Carers were asked to withhold the study drug if the child
developed diarrhea, blood in stools or unexplained
bruising, and to bring the child for assessment as soon
as possible. The study drug was suspended until diar-
rheal episodes had resolved.
All children received nutritional rehabilitation with
ready-to-use therapeutic foods (RUTF) conforming to
WHO/UNICEF standards until they were nutritionally
cured of SAM (MUAC >11.5 cm and no edema at two
consecutive weekly visits), alongside a seven-day course
of amoxicillin and deworming with mebendazole or alben-
dazole according to Kenyan national guidelines [30].
Outcomes
Primary outcomes were frequency of adverse events and
compliance with the intervention, assessed via interview
with the carer and weekly counting of full/empty sachets.
Stool frequency and consistency was assessed at each
study visit using a Kiswahili translation of the Bristol Stool
Form Scale [see Additional file 1] [31]. Secondary out-
comes were time to recovery, growth and a panel of
inflammatory markers (see below).
Laboratory methods
Blood tests designated for safety (full blood count, ESR,
C-reactive protein, creatinine, alanine transaminase (ALT),
aspartate aminotransferase (AST), gamma-glutamyl trans-
peptidase (GGT), bilirubin) and stool for microscopy were
processed in a commercial good clinical laboratory practice
(GCLP)-accredited laboratory in Nairobi (Pathologists
Lancet Kenya) and results were provided the following day.
Plasma, serum and stool were kept on ice prior to
freezing at −80°C pending batched enzyme-linked im-
munosorbent assay (ELISA) processing. The following
were tested by ELISA following the manufacturers’ rec-
ommendations: fecal calprotectin (Bühlmann Laborator-
ies AG (Schönenbuch, Switzerland) kits on stool following
disruption by 30 seconds TissueLyser shaking (QIAGEN
(Hilden, Germany), no beads)), plasma anti-endotoxin core
immunoglobulin G (IgG EndoCAb, Hycult Biotech (Uden,
The Netherlands)), plasma interferon-γ (Ebioscience (San
Diego, California, USA)) and serum insulin-like growth
factor-1 (R&D Systems (Minneapolis, Minnesota, USA)).
Muliplex ELISA (Luminex (Austin, Texas, USA) MAGPIX
system) was performed against the following targets in
plasma: Eotaxin (chemokine (C-C motif) ligand (CCL)-11),
GROα (growth regulated oncogene-α, chemokine (C-X-C
motif) ligand (CXCL)-1), interferon-α, interleukin (IL)-1α,
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IL-17a, IL-22, IL-31, IP-10 (interferon-γ induced protein-
10, CXCL10), MCP-1 (monocyte chemotactic protein-1,
CCL2), MIP-1α (macrophage inflammatory protein-1α,
CCL3), MIP-1β (CCL4), SDF-1 (stromal cell-derived
factor-1, CXCL12) and tumor necrosis factor-β (TNFβ)
(Ebioscience). Soluble CD14 (sCD14) was measured
using an in-house ELISA (capture clone 55–3, detec-
tion clone 3-C39 both from BD (Franklin Lakes, New
Jersey, USA), recombinant standard from Sigma-Aldrich
Limited (Gillingham, United Kingdom)). Serum endotoxin
was measured using HEK-Blue Endotoxin Detection Kit
(Invivogen (San Diego, California, USA)): This test relies
on a HEK293 cell line that has been stably transfected
with Toll-like receptor 4 pathway genes and a secretory al-
kaline phosphatase that is transcriptionally regulated by
NF-κB. Heat-inactivated sera (90°C for 30 minutes) were
incubated in duplicate with cells for 24 hours in the pres-
ence of a detection reagent. Absorption at 620 nm was
read against a standard curve.
Statistical methods
Analysis was performed in STATA Version 12.0. We
performed Mann–Whitney U tests or t-tests on log-
transformed data between the arms at each time point.
Growth in height and MUAC across the trial was cal-
culated for individual participants in mm/day and
compared using Mann–Whitney U tests. Fisher’s exact
test was used to compare grouped variables. Compari-
son of the timing of adverse events was done using
logrank. Raw ELISA data was analyzed in Graphpad
Prism 6.0 prior to import into STATA and z-scores were
calculated using WHO Anthro Version 3.2.2 STATA
macros. Analyses were performed by intention to treat,
except for blood and stool laboratory analyses, which were
performed using data from all available specimens (that is,
not including data missed due to withdrawal or failure to
get specimens). For this pilot study, no cut-off was consid-
ered to indicate ‘statistical significance’, and P-values
are provided throughout. Because the secondary analyses
were intended to be exploratory and hypothesis-
generating, post-hoc correction for multiple compari-
sons was not performed.
Sample size was set at 22 in each arm with reference
to norms in Phase I and early Phase II research. No sam-
ple size calculation was performed and the study was
not powered to formally address any outcomes at any
given significance level.
Study oversight
All participants enrolled in the study had individual writ-
ten informed consent provided by a parent or guardian.
The study was approved by the Kenya Medical Research In-
stitute (KEMRI) Ethical Review Committee, the ImperialCollege, London, Ethical Review Committee, and the Kenya
Pharmacy & Poisons Board prior to initiation. Imperial
College, London, was the sponsor. Clinical trials monitoring
was performed by staff from the Clinical Trials Facility,
KEMRI-Wellcome Trust Research Programme. An inde-
pendent Data Safety and Monitoring Board (DSMB) was
established and an independent consultant pediatrician acted
as local safety monitor. Neither the sponsor nor any other
party except the named investigators had any role in
the design of the study, interpretation of the results, content
of manuscripts or decision to publish. The trial was regis-
tered at http://clinicaltrials.gov/ct2/show/NCT01841099.
Results
From June to September 2013, 133 children with SAM
and stunting were screened for eligibility. Forty-four
children completed screening procedures and were eli-
gible, all of whom were enrolled (Figure 1). The arms
were well balanced in terms of clinical, anthropometric
and demographic characteristics at baseline (Table 1).
Follow-up and compliance
Following completion of the interventional phase of the
study at day 28, one child in each arm was voluntarily
withdrawn from the study by their carer (in both cases
because the family planned to travel away from Nairobi)
and one child in each arm was lost to follow-up. Com-
pliance with the study drug administration schedule was
high in both arms (Table 2). Early discontinuation of the
study drug occurred in three children, in each case for
reasons unrelated to the drug itself and all three
remained in follow-up: one discontinuation at day 14
was at parental request, another at day 14 was initiated
by the study team because the parent was unable to give
the drug as prescribed, and the third at day 22 was be-
cause the participant was taken into protective custody.
All three were in the mesalazine arm.
Adverse events and toxicity
Two children required hospitalization during the course
of the study, both with diarrhea, dehydration and sepsis,
one of whom died. Both were in the placebo arm. One
child in each arm was started on tuberculosis treatment
on the basis of clinical score and poor response to nutri-
tional rehabilitation. One child in the placebo arm was
newly diagnosed with sickle cell disease.
Non-severe adverse events and illness episodes were
common, as expected in this vulnerable patient popula-
tion, but there was no suggestion of excess risk associ-
ated with mesalazine treatment either in total adverse
events, adverse events involving the gastrointestinal tract,
or those associated with diarrhea (Table 2 and Figure 2A).
At day 7, children in the mesalazine arm had firmer stool
consistency (Figure 2B, 2C).
133 Children aged 12-60 months with Severe Acute Malnutrition, stunting and 
without known HIV infection were screened for eligibility 
89 were not eligible: 
   83 did not meeting inclusion criteria*  
2 not stunted when rechecked  
3 had bloody diarrhoea  
3 had severe cerebral palsy  
7 required admission  
1 was already receiving RUTF  
3 were diagnosed with HIV  
1 started TB treatment  
10 had malaria  
11 had hepatic dysfunction  
49 had ESR<20mm/h  
   3 declined to participate  
   3 absconded during screening 
22 were randomized to mesalazine 22 were randomized to placebo 
44 were randomized 
20 completed follow-up as planned 
1 voluntary withdrawal 
1 loss to follow-up 
3 discontinued study drug early 
1 voluntary parental request 
1 parent not able to give drug safely 
1 child taken into care 
19 completed follow-up as planned 
1 death 
1 voluntary withdrawal 
1 loss to follow-up 
0 discontinued study drug early 
22 were included in analysis 22 were included in analysis 
Figure 1 Trial flow diagram: *Some children had multiple reasons for being ineligible.
Jones et al. BMC Medicine 2014, 12:133 Page 6 of 14
http://www.biomedcentral.com/1741-7015/12/133The most common previously reported side-effects of
mesalazine, apart from gastrointestinal problems, are
headache and rash. Most children were pre-verbal and
would have been unable to report headache but there
were no concerns from carers about irritability, restless-
ness or problems with sleeping. Four children had an in-
fectious rash during the course of the study but none
were considered related to treatment: two had impetigo
(both mesalazine arm), one had chickenpox (placebo)
and one had scabies (placebo).
Dose escalation at day 7 was delayed in eight partici-
pants: seven had developed elevated transaminases com-
pared to their enrollment results and one child was
admitted to hospital on the day of their scheduled visit.
Of these eight participants, seven were in the placebo
arm and one was in the mesalazine arm. Transient ele-
vation of liver enzymes compared to enrollment was
common at day 7 and was more pronounced in the pla-
cebo arm (Figure 2D, 2E). No Grade 3 or 4 toxicities
were encountered in the study.
Creatinine concentrations across the trial were low. A
single elevated concentration occurred at day 56 in a
child in the mesalazine arm who had achieved nutri-
tional recovery (Figure 2F). The child remained well and
when tested three months later the creatinine concentra-
tion was 27 μmol/L.Thirty-four (77%) children were anemic (Hb <11.0 g/dL)
at enrollment. Rates of resolution were similar in the two
arms (Figure 2G).
Growth and recovery
At completion of the 56-day follow-up period, nine-
teen children (34%) had not recovered, had died, or
were not remaining in follow-up, nine in the mesala-
zine arm and ten in the placebo arm. At day 56, there
were no differences in RUTF-free days or resolution of
edema between the arms (Table 2). The rate of in-
crease in MUAC was higher in the placebo than in the
mesalazine arm, although this was less pronounced
among those children who were enrolled without
edema [see Additional file 1]. There were no differ-
ences in linear growth rate or change in height-for-age
z-score (Table 2).
Insulin-like growth factor-1 (IGF-1) increased from
enrollment to day 28 in both arms, and was maintained
to day 56 (Figure 3A). Enrollment IGF-1 concentration
had a strong inverse correlation with a number of in-
flammatory mediators (for example, C-reactive protein
(CRP), P = 0.008), which was less apparent at the later
time points (Figure 3B). IGF-1 concentrations at day 28
correlated strongly with the rate of height growth both
to day 28 and day 56 (Figure 3C).
Table 1 Baseline characteristics
Baseline characteristics Mesalazine arm Placebo arm
Number enrolled 22 22
Age (months) 19 (14 to 32) 19 (15 to 29)
Sex: Male 10 (45) 11 (50)
Female 12 (55) 11 (50)
Household income
category (USD/day)a
$2 to $4 $2 to $4
Number of people living
in the house




Access to improved toilet
facility
50% 41%
MUAC (cm) 12.9 (11.2 to 14.4) 12.7 (11.2 to 13.8)
Height-for-age z-score −3.13 (−3.83 to -2.71) −3.73 (−4.60 to -2.81)
Nutritional edema 15 (68) 17 (77)
Current breastfeedingc 11 (50) 5 (23)
Symptoms: Fever 10 (45) 8 (36)
Cough 9 (41) 6 (27)
Diarrhea 5 (23) 5 (23)
Biochemistry: Creatinine
(umol/L)
18 (17 to 23) 19 (17 to 22)
AST (IU/L) 37 (27 to 52) 40 (32 to 49)
ALT (IU/L) 24 (12 to 31) 17 (15 to 30)
CRP (mg/L) 6.0 (1.3 to 10.8) 6.8 (1.6 to 42.2)
Hematology: Hemoglobin
(g/dL)
10.3 (7.9 to11.2) 9.6 (8.2 to 10.6)
WBC count (x 109/L) 12.0 (9.9 to 15.1) 11.8 (9.3 to 13.6)
Platelet count (x 109/L) 555 (423 to 666) 536 (282 to 692)
ESR (mm/hour) 32 (24 to 38) 33 (28 to 44)
aMedian and IQR for both arms all fell within the $2 to $4 category. bMostly
communal taps from which water must be purchased. Lack of resources was
reported to limit access. cP = 0.06. Data are medians (inter-quartile range) or
numbers (%). ALT, alanine transaminase; AST, aspartate aminotransferase; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; MUAC, mid-upper arm
circumference; WBC, white blood cell.
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Intestinal inflammation was evident in most children at
enrollment, with 43 (97%) having fecal calprotectin higher
than 100 μg/g [32]. Systemic inflammatory activation was
evident, which declined during the course of the trial.
Point estimates of most of the clinically important or gut-
specific inflammatory markers were lower in the mesala-
zine arm on completion of treatment at day 28 (Figure 4).
Differences between the arms were not sustained to day
56. Cytokine concentrations in plasma were similar be-
tween the arms at all time points [see Additional file 1].
Discussion
This is the first controlled trial of a directly immuno-
modulatory agent in children with SAM. Despite beingeligible for outpatient management with ‘uncomplicated’
SAM, intestinal and systemic inflammatory activation
was very common. Baseline levels of fecal calprotectin
were higher than has been reported from healthy control
populations in high-income countries and sub-Saharan
Africa, approaching those seen in active IBD [33,34].
Treatment with mesalazine was safe. The frequency of
acute illness episodes was similar in both arms, and
there was no excess gastrointestinal morbidity to suggest
a disadvantageous effect on gut mucosal homeostasis.
The trial was not intended to be powered to detect rates
of resolution of edema, recovery of acute malnutrition
or linear growth. Individual growth trajectories revealed
greater MUAC growth in the placebo arm to day 56 but
because edema can alter MUAC and most of the chil-
dren in this study were edematous at enrollment, the
clinical significance is unclear.
In pediatric IBD, linear growth impairment correlates
with cytokine-mediated depression of the growth hor-
mone – IGF-1 axis, and a similar effect was evident
among participants in this trial [35–37]. It is, therefore,
encouraging that the mesalazine arm achieved modest
reductions in multiple clinically-relevant and gut-specific
biomarkers compared to placebo after 28 days treat-
ment. If EED represented an essential level of inflamma-
tory activation and immune-surveillance in the face of a
high pathogen burden, we would have expected the op-
posite result: that mesalazine would have been associ-
ated with a loss of control at the gut mucosal surface,
increased levels of bacterial translocation and systemic
immune activation, alongside development or worsening
of gastrointestinal symptoms. Instead, we have demon-
strated that pharmacologically-mediated reduction in en-
teric inflammation is well tolerated, thereby providing
the first clear evidence that EED is likely to be at least
partly maladaptive and, consequently, a potential direct
target for therapy. New therapies are urgently required
because trials of nutritional support, hygiene-based in-
terventions, probiotics and empiric treatment for small
intestinal bacterial overgrowth or specific pathogens
have failed to show clinically significant improvements
in linear growth or EED activity in children [4,38–40].
We suggest that failure to control host-driven inflamma-
tory activation may have been a barrier to efficacy of
these interventions.
An important limitation of our study is that enteric in-
flammation is inferred on the basis of indirect blood or
fecal markers. A recent expert working group concluded
on the basis of the myriad ethical and logistical chal-
lenges inherent in performing gastrointestinal endoscopy
on young children, that ‘definition of environmental enteric
dysfunction will need to rely on biomarkers alone, without
biopsy data to connect functional and structural changes’
[1]. Importantly, the high levels of fecal calprotectin and
Table 2 Outcomes
Mesalazine arm Placebo arm P
Safety and compliance
Deaths 0 1 0.32
Hospitalizationsa 0 2 0.15
Total adverse events 35 27 0.53
Acute watery diarrhea 7 8 0.53
Bloody diarrhea 0 2 0.32
Chronic diarrhea 1 1 1.00
Gastroenteritis (with vomiting) 5 1 0.15
Giardiasis 6 6 1.00
Oral candidiasis 3 0 0.08
Upper respiratory tract infection 3 5 0.64
Lower respiratory tract infection 3 1 0.30
Tuberculosis 1 1 1.00
Malaria/non-specific febrile illness 4 3 0.43
Rash 2 2 1.00
Total gastrointestinal adverse events 23 16 0.27
Total diarrheal adverse events 8 11 0.65
Unable to dose-escalate at day 7 1 (5) 7 (32) 0.05
Compliance (%) 93 (71 to 98) 97 (82 to 99) 0.44
Anthropometry and recovery
Recovery: nutritionally cured at day 56 13 12 1.00
Recovery: RUTF-free days at day 56 9 (0 to 21) 9.5 (0 to 21) 0.94
Nutritional edema Baseline 15/22 (68) 17/22 (77) 0.72
Day 28 7/22 (32) 6/22 (27) 1.00
Day 56b 3/20 (15) 2/19 (11) 1.00
MUAC (mm) Baseline 12.9 (11.2 to 14.4) 12.7 (11.2 to 13.8) 0.56
Day 28 13.7 (11.8 to 14.7) 13.2 (12.2 to 14.6) 0.82
Day 56 13.9 (12.5 to 14.8) 13.6 (13.0 to 15.1) 0.59
MUAC growth rate (mm/day) To day 28 0.23 (0.06 to 0.37) 0.31 (0.18 to 0.61) 0.15
To day 56 0.12 (0.08 to 0.21) 0.23 (0.14 to 0.33) 0.01
Height growth rate (mm/day) to day 56 0.31 (0.19 to 0.38) 0.32 (0.21 to 0.38) 0.94
Height-for-age z-score Baseline −3.13 (−3.83 to -2.71) −3.73 (−4.60 to -2.71) 0.29
Day 28 −3.17 (−4.04 to -2.61) −3.70 (−4.20 to -2.73) 0.42
Day56 −3.24 (−4.10 to -2.68) −3.46 (−4.14 to -2.68) 0.79
aIncludes the one child who died in hospital. bExcluding children who were unable to be assessed. Data are medians (inter-quartile range) or numbers (%) unless
otherwise stated. MUAC, mid-upper arm circumference; RUTF, ready-to-use therapeutic food.
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are more consistent with inflammation in the colon than in
the small intestine [41–43]. In view of the fact that sigmoid-
oscopy can be achieved far more easily than full colonos-
copy and without the need for bowel preparation or deep
sedation, if colonic inflammation were a major component
of EED, it might be substantially more amenable to serial
tissue-based monitoring in clinical trial settings. Biopsystudies of colonic architecture in children at risk of EED
have not been reported to our knowledge.
The enrollment of children who were severely acutely
malnourished as well as stunted was ethically appropri-
ate because children with SAM are at the highest risk of
continued growth disturbance, illness and death, mean-
ing that they have the most to gain from any potential
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Figure 2 Safety and toxicity. Cumulative timing of adverse events between the arms (A). Stool consistency (Bristol Stool Form Scale) and
frequency in the 24 hours preceding clinical review (B,C). Hepatic enzymes, aspartate aminotransferase (AST), alanine transaminase (ALT) and
gamma-glutamyl transpeptidase (GGT), for all participants in the study (D). Change in hepatic enzymes from baseline to day 7 (E). Creatinine and
hemoglobin for all participants (F,G). Differences between arms at baseline are highlighted if P <0.1, upper limit of normal (alongside lower limit
for creatinine) illustrated where appropriate.
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http://www.biomedcentral.com/1741-7015/12/133suggest a maladaptive inflammatory enteropathy, it may
be that ensuring optimal capacity to respond to a new
pathogen challenge takes precedence over optimizing
growth in the context of SAM, where vulnerability to
major infection is intense. Targeting those with moder-
ate acute malnutrition or non-acutely malnourished chil-
dren would be likely to increase the chances of detecting
any nascent IGF-1-mediated linear growth benefit and
presents the most plausible scenario under which such
interventions could be used in the field. In this regard, a
limitation of the study is that the inflammatory enterop-
athy found in kwashiorkor (which was present in 73% of
those enrolled) may be qualitatively different than that
present in the context of other forms of acute malnutrition,and to the form of EED that appears to be prevalent with
stunting. Results of the current trial should not be consid-
ered generalizable either to children with stunting but
without acute malnutrition or to populations of moderately
or severely malnourished children without high prevalence
of kwashiorkor, and future studies in such groups will need
to take a similarly cautious and thorough approach as we
have here [12]. That said, such studies should consider the
use of more intensive treatment schedules because al-
though mesalazine is a good agent for maintenance of re-
mission in IBD, it is less effective in induction. Difficulty in
diagnosing tuberculosis in acutely malnourished children
may preclude the use of systemic immunosuppressants,
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Figure 3 IGF-1 and growth. Insulin-like growth factor-1 (IGF-1) increases during follow-up (A). Enrollment IGF-1 had negative correlations with
several inflammatory markers (B, color indicates statistical significance level, + or – indicates a positive or negative correlation). This effect reduced
between IGF-1 and concurrent inflammatory markers at later time points. Concentrations of IGF-1 and endotoxin correlated positively and
negatively (respectively) with linear growth over the course of the study (C).
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http://www.biomedcentral.com/1741-7015/12/133reasonably be trialed. Furthermore, although EED occurs
in all age groups, irreversible stunting mainly occurs in
the first two years of life, and may even be apparent at
birth [15,44]. Treatment prior to the development of
clear evidence of growth failure may be optimal, butthis requires the development and refinement of point-
of-care biomarkers for EED. Fecal calprotectin may be
a suitable marker: point-of-care tests already exist, and
evaluation against dual sugar absorption tests (cur-
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Figure 4 Impact on inflammatory activation. Key clinically important and gut-specific inflammatory markers between arms. Differences at
baseline are highlighted if P <0.1. Upper limit of normal illustrated where appropriate.
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http://www.biomedcentral.com/1741-7015/12/133should be a research priority. The possibility of target-
ing short-term medical treatments towards this key
early window of vulnerability to linear growth failure,
which is also the peak period for development of acute
malnutrition and major infectious diseases, means that
clinical benefit for individual children might be pos-
sible even if modification of environmental determi-
nants was minimal. This reflects social and political
realities in many of the settings where EED is endemic.
Our results have highlighted that elevation of liver en-
zymes is reasonably common in uncomplicated SAM
(8% of those screened) and that current management
strategies may be associated with a transient exacerba-
tion. Fatty infiltration of the liver is a recognized feature
of kwashiorkor and could be exacerbated by a sudden
switch towards a plentiful and very high-fat diet [45].
That RUTF is safe and effective for use in the commu-
nity is partly a factor of its high lipid content (which re-
stricts bacterial growth) and it is likely that any risk
associated with modest increase in liver enzymes is out-
weighed by the proven benefits of community-based
care. However, there may be a subset of patients in
whom this presents a particular problem, especially as
RUTF is starting to be used more commonly in the
more-unwell group of hospitalized severely acutely mal-
nourished children.
The participants involved in this trial represented a
uniquely vulnerable population. Detection of a severely
acutely malnourished child during community screening
was frequently an indicator of multiple social, nutritional
and medical problems affecting the whole family. The
provision of appropriate ancillary support was an essential
component of our trial methodologies, made possible be-
cause of the comprehensive integration of medical and
social services and long history of community engage-
ment in Mathare by ‘German Doctors’, which made
this setting a particularly appropriate one in which to
conduct the trial. Where required, parents and siblings
were provided with a daily food ration, free medical
care and access to social support and advice. Study
visits took place at participants’ home to minimize the
opportunity cost of attending the clinic and commu-
nity health workers performed regular home visits in
order to provide support and assess for additional
needs. The same benefits were afforded to all children
screened for enrollment regardless of their eligibility.
Conclusions
In summary, we have reported the first controlled trial
directly targeting the host inflammatory response in
children with SAM. The trial is conceptually novel in
considering EED as a maladaptive host response to en-
vironmental challenge and has provided pilot evidence
of safety. Larger trials will be needed to assess efficacybut our finding of concordance of a range of inflamma-
tory markers encourages the design of such studies.
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